The time frame depends on how quickly Amarantus submits the
The time frame depends on how quickly Amarantus submits the IND paperwork to the FDA. Sometimes the FDA will immediately grant Orphan status along with the ok to start P1 trials and sometimes it takes longer.
I believe the company would like to get at least the first MANF submission by EOY, if I am not mistaken.
And while it's great that it keeps identifying uses for MANF, it won't do much until AMBS actually submits the IND paperwork.
Amarantus Bioscience Holdings (AMBS) Stock Research Links
My Agenda: To see Amarantus prosper so I can make a nice return on my investment.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
No Smooth Sailing in HBX's Waters Tell you what, HBX Group's third-quarter update feels like a mixed bag of tricks. They’ve pulled off a decent 12% boost in Total Transaction Value (TTV), hitting €2.4 billion. Now, that’s an eyebrow-raiser in this market, especially when leisure travel's still rebounding. But, and there’s always a but, revenue's slid 3%...
Continue Reading
Beam Global Announces Strong Second Quarter Results Beam Global, a renowned provider of sustainable infrastructure solutions focused on electrification and energy security, has recently unveiled impressive financial results for the second quarter. This announcement reinforces Beam's commitment to growth and innovation within the clean energy sector. Financial Highlights...
Continue Reading
Dispelix and RTX's Collins Aerospace Join Forces Dispelix, a leader in augmented reality (AR) waveguide display technology, and Collins Aerospace, part of RTX, have embarked on a transformative partnership. This collaboration is centered around a long-term supply agreement aimed at integrating Dispelix's cutting-edge AR waveguide displays into Collins Aerospace's...
Continue Reading
Dundee Precious Metals Provides Update on the ?oka Rakita Project Today, Dundee Precious Metals Inc. (TSX: DPM) announced important updates regarding the ?oka Rakita project. The company's latest report confirms that the pre-feasibility study (PFS) is set for completion in early 2025, indicating a positive trajectory for the project's growth. Additionally, new assay...
Continue Reading
Citi Adjusts Cadence BanCorp Price Target Citi has recently updated its outlook for Cadence BanCorp (NYSE: CADE), maintaining a Neutral rating while elevating the price target to $37 from $35. This revision comes as analysts foresee continued net interest margin (NIM) expansion paired with prudent cost management strategies that are expected to benefit the bank in the...
Continue Reading
